-
MMW Fortschritte Der Medizin Aug 2023
Topics: Humans; Antihypertensive Agents; Indapamide; Amlodipine
PubMed: 37537471
DOI: 10.1007/s15006-023-2868-1 -
MMW Fortschritte Der Medizin Feb 2024
Topics: Humans; Antihypertensive Agents; Indapamide; Amlodipine
PubMed: 38389023
DOI: 10.1007/s15006-024-3667-z -
Expert Review of Clinical Pharmacology Nov 2018Osteoarthritis constitutes one of the leading causes of pain and disability worldwide with a significant impact on health-care costs. Patients with osteoarthritis are... (Review)
Review
Osteoarthritis constitutes one of the leading causes of pain and disability worldwide with a significant impact on health-care costs. Patients with osteoarthritis are often affected by a number of cardiovascular comorbidities, including hypertension, which is present in about 40% of cases. Just recently, a single tablet combination of amlodipine besylate, a calcium channel blocker, and celecoxib, a nonsteroidal anti-inflammatory drug, indicated for patients for whom treatment with amlodipine for hypertension and celecoxib for osteoarthritis are appropriate, has been recently approved. Areas covered: We reviewed data from clinical studies that investigated safety and efficacy of the combination of amlodipine and celecoxib in hypertensive patients with osteoarthritis published before 31 August 2018. The literature search was conducted using research Methodology Filters. Expert commentary: The advantages of this single formulation over sequential administration include increased compliance, possibly reduced cost, and less likelihood of dosage-related issues. Moreover, this single tablet formulation combines the anti-inflammatory activity of the celecoxib with the systemic vasodilatation induced by the amlodipine. It is a promising treatment for patients with osteoarthritis and hypertension. Nevertheless, celecoxib may cause a variable degree of blood pressure increase and only a small clinical trial has been conducted before approval to assess interactions related to blood pressure effect between these two molecules.
Topics: Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Celecoxib; Drug Combinations; Humans; Hypertension; Osteoarthritis; Pain
PubMed: 30362840
DOI: 10.1080/17512433.2018.1540299 -
American Journal of Cardiovascular... Oct 2015Perindopril, an ACE inhibitor, and amlodipine, a dihydropyridine calcium channel blocker, are established antihypertensive agents with complementary mechanisms of... (Review)
Review
Perindopril, an ACE inhibitor, and amlodipine, a dihydropyridine calcium channel blocker, are established antihypertensive agents with complementary mechanisms of action. Recently, a once-daily, orally-administered, fixed-dose combination (FDC) of perindopril arginine plus amlodipine besylate (Prestalia(®); hereafter referred to as perindopril/amlodipine FDC) was approved in the USA for the treatment of hypertension. This article reviews the efficacy and tolerability of perindopril/amlodipine FDC and briefly summarizes the agent's pharmacologic properties. As demonstrated in short-term randomized controlled trials, perindopril/amlodipine FDC was significantly more effective in reducing blood pressure (BP) than monotherapy with either of the component drugs, and it appeared to be more effective than an up-titration scheme using valsartan and valsartan/amlodipine. The FDC agent was generally well tolerated, with the most common adverse events (peripheral edema, cough, headache, and dizziness) being consistent with the well-defined tolerability profiles of the individual component drugs. Furthermore, perindopril/amlodipine FDC was associated with a numerically lower incidence of peripheral edema compared with amlodipine monotherapy. Thus, perindopril/amlodipine FDC represents a useful option for the treatment of hypertension, including as initial therapy for patients likely to require multiple drugs to achieve their BP targets.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Drug Combinations; Drug Interactions; Humans; Hypertension; Perindopril; Randomized Controlled Trials as Topic
PubMed: 26341621
DOI: 10.1007/s40256-015-0144-1 -
American Journal of Therapeutics
Topics: Humans; Pigmentation Disorders; Amlodipine; Calcium Channel Blockers
PubMed: 33590988
DOI: 10.1097/MJT.0000000000001317 -
Clinical Medicine (London, England) Jul 2022
Topics: Amlodipine; Humans; Hyponatremia; Risk Factors
PubMed: 36220214
DOI: 10.7861/clinmed.22-4-s41 -
Management of Hypertension With a Fixed-Dose (Single-Pill) Combination of Bisoprolol and Amlodipine.Clinical Pharmacology in Drug... Jan 2017Hypertension is currently one of the greatest global health care challenges. Although many effective drugs are available, combinations of 2 or more medications are often...
Hypertension is currently one of the greatest global health care challenges. Although many effective drugs are available, combinations of 2 or more medications are often required to meet clinical targets. Combination therapy has several advantages over monotherapy: lower doses of each drug can be used to achieve therapeutic goals; lower doses may lead to fewer adverse events, facilitating patient adherence; and using multiple drugs with different modes of action may be more effective in treating multifactorial diseases, including hypertension. Adherence is an important consideration when requiring patients to self-administer multiple medications; as the number of concurrent medications increases, patient adherence tends to decrease. Recent evidence suggests that fixed-dose combinations (FDCs) may be more effective than free-dose combinations, as they provide all necessary medications in a single convenient tablet/single-pill combination. Among combinations of hypertension medications, a β-blocker such as bisoprolol with a calcium channel blocker such as amlodipine is an effective combination therapy for hypertension, with distinct and complimentary modes of action. With advantages over free-dose combinations, the FDC of bisoprolol/amlodipine is thus an effective and convenient treatment for hypertension, allowing more patients to achieve their therapeutic goals, while potentially reducing the burden of hypertension on health care systems.
Topics: Amlodipine; Antihypertensive Agents; Bisoprolol; Clinical Trials as Topic; Drug Combinations; Humans; Hypertension; Patient Compliance; Treatment Outcome
PubMed: 27653022
DOI: 10.1002/cpdd.309 -
Journal of Hypertension Jul 2023SBP and blood pressure variability are independent risk factors for cerebral small vessel disease, a leading cause for stroke and dementia. Calcium-channel blockers are...
BACKGROUND
SBP and blood pressure variability are independent risk factors for cerebral small vessel disease, a leading cause for stroke and dementia. Calcium-channel blockers are known to reduce blood pressure variability and may thus offer benefit against dementia. Beyond this effect, the impact of calcium-channel blockers on hypertension-induced neuroinflammation, and especially, microglial phenotype remains unknown. We aimed to study the ability of amlopidine to alleviate microglia inflammation, and slow down cognitive dysfunction in aged hypertensive mice.
METHODS
Hypertensive BPH/2J and normotensive BPN/3J mice were studied until 12 months of age. Hypertensive mice were untreated or received amlodipine (10 mg/kg per day). Blood pressure parameters were measured by telemetry and tail cuff plethysmography. Mice underwent repeated series of cognitive tasks. Brain immunohistochemistry was performed to study blood-brain barrier dysfunction and microglial pro-inflammatory phenotype (CD68 + Iba1 + cells; morphological analysis).
RESULTS
Amlodipine normalized SBP over the entire life span and decreased blood pressure variability. BPH/2J mice exhibited impaired short-term memory that was prevented by amlodipine at 12 months (discrimination index 0.41 ± 0.25 in amlodipine-treated vs. 0.14 ± 0.15 in untreated BPH/2J mice, P = 0.02). Amlopidine treatment of BPH/2J did not prevent blood-brain barrier leakage, a measure of cerebral small vessel disease, but limited its size. Microglia's inflammatory phenotype in BPH/2J, characterized by an increased number of Iba1 + CD68 + cells, increased soma size and shortened processes, was partly reduced by amlodipine.
CONCLUSION
Amlodipine attenuated the short-term memory impairment in aged hypertensive mice. Beyond its blood pressure lowering capacity, amlodipine may be cerebroprotective by modulating neuroinflammation.
Topics: Animals; Mice; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium; Calcium Channel Blockers; Dementia; Hypertension; Microglia; Neuroinflammatory Diseases
PubMed: 37071429
DOI: 10.1097/HJH.0000000000003445 -
Hypertension (Dallas, Tex. : 1979) Feb 2022
Topics: Adolescent; Amlodipine; Antihypertensive Agents; Humans; Hypertension; Male; Treatment Outcome
PubMed: 34955036
DOI: 10.1161/HYPERTENSIONAHA.121.18011 -
Journal of Nuclear Cardiology :... Aug 2023Anti-hypertensive drugs can improve vascular endothelial function. However, the mechanism remains to be elucidated. (Randomized Controlled Trial)
Randomized Controlled Trial
BACKGROUND
Anti-hypertensive drugs can improve vascular endothelial function. However, the mechanism remains to be elucidated.
OBJECTIVES
This study sought to investigate mechanisms of anti-hypertensive drugs on improvement of vascular endothelial function in patients with essential hypertension.
METHODS
Forty-five patients (mean age 58.5 ± 11.2 years) with uncontrolled essential hypertension were randomly assigned to receive olmesartan, an angiotensin II type 1 receptor blocker (ARB) (N = 23), or amlodipine, a calcium channel blocker (CCB) (N = 22), for 6 months. Endothelial function was evaluated by flow-mediated dilatation (FMD) of the brachial artery. Vascular inflammation was measured by blood-normalized standardized uptake value, known as a target-to-background ratio (TBR) within the carotid arteries using 18F-fluorodeoxyglucose-positron emission tomography combined with computed tomography.
RESULTS
There were no significant differences of baseline clinical data between the ARB and CCB groups. Both anti-hypertensive drugs comparably lowered blood pressure and increased %FMD. TBR values were reduced by olmesartan (P < .001), while blood pressure variability was decreased by amlodipine (P = .004). Changes in %FMD from baseline (Δ%FMD) were inversely associated with ΔTBR in the olmesartan group (r = - .606, P = .003) and with Δsystolic blood pressure variability in the amlodipine group (r = - .434, P = .039).
CONCLUSION
Our study indicated that olmesartan and amlodipine could improve endothelial function in patients with essential hypertension in different manners, suppression of vascular inflammation, and decrease in blood pressure variability, respectively.
Topics: Humans; Middle Aged; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Hypertension; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Essential Hypertension; Inflammation; Drug Therapy, Combination
PubMed: 36737518
DOI: 10.1007/s12350-023-03200-y